CVAC News & Events

Inventiva (IVA) announced three new members of its leadership team: Axel-Sven Malkomes as CFO, Susan Coles as chief legal officer, and Pamela Herbster as chief people officer. Former CFO Jean Volatier will transition to the role of EVP finance and corporate social responsibility, where he will continue to support the company on strategic priorities. Malkomes was most recently CFO at publicly CureVac (CVAC). Coles comes to Inventiva from Vivet Therapeutics, where she was head of legal and finance. Herbster comes to Inventiva from Sage Therapeutics, where she led both human resources and business operations.

Evotec (EVO) announced the appointment of Ingrid Muller as COO. Muller will be joining Evotec's management board, effective May 1. In her role as COO, Muller will oversee Evotec's global operations and implementation of the Horizon initiative. Most recently, Muller served as VP portfolio strategy and execution at CureVac (CVAC).

BioNTech (BNTX) announced that 184,071,410 shares of CureVac (CVAC), representing approximately 81.74% of CureVac's issued and outstanding shares, were validly tendered and not properly withdrawn prior to the expiration of the initial offering period at 9:00 a.m. Eastern Time on December 3, 2025. As a result, the minimum condition for the exchange offer has been satisfied, and all validly tendered shares have been accepted. All closing conditions related to the completion of the post-offer reorganization have now been satisfied. BioNTech will now proceed to deliver BioNTech American Depositary Shares to the holders of CureVac shares who have tendered their shares, to close the transaction, as set out in more detail in the offer documents. BioNTech also announced that the subsequent offering period has commenced. CureVac shareholders who have not yet tendered their shares may still tender during the subsequent offering period, which will expire at 12:01 a.m. Eastern Time on Thursday, December 18, 2025. No guaranteed delivery procedures apply. The parties will initiate the post-offer reorganization as promptly as practicable following the expiration of the subsequent offering period. The post-offer reorganization will result in non-tendering holders of CureVac shares receiving BioNTech ADSs pursuant to the post-offer reorganization. Non-tendering holders of CureVac shares who receive BioNTech ADSs pursuant to the post-offer reorganization generally will be subject to a 15% Dutch dividend withholding tax.